Evidence map›Paper›PMID 40090543›Full record

Trial reportThe Journal of pediatrics2025

Patent Ductus Arteriosus, Hydrocortisone, and Outcome among Infants Born Extremely Preterm: Secondary Analysis of the Hydrocortisone Trial.

Meera N Sankar, Valerie Chock, Faith Myers, Alexis S Davis, Scott McDonald, Matthew A Rysavy, Matthew Laughon, Shazia Bhombal, Krisa P Van Meurs, Abhik Das and 3 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Meera N SankarDivision of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine and Lucile Packard Children's Hospital, Palo Alto, CA. Electronic address: mnsankar@stanford.edu.
Valerie ChockDivision of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine and Lucile Packard Children's Hospital, Palo Alto, CA.
Faith MyersChildren's Health Care of Minnesota, Minneapolis, MN.
Alexis S DavisDivision of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine and Lucile Packard Children's Hospital, Palo Alto, CA.
Scott McDonaldRTI International, Research Triangle Park, NC.
Matthew A RysavyDepartment of Pediatrics, McGovern Medical School at UTHealth Houston, Houston, TX.
Matthew LaughonDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, NC.
Shazia BhombalEmory University/Children's Healthcare of Atlanta, Atlanta, GA.
Krisa P Van MeursDivision of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine and Lucile Packard Children's Hospital, Palo Alto, CA.
Abhik DasRTI International, Research Triangle Park, NC.
William E BenitzDivision of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine and Lucile Packard Children's Hospital, Palo Alto, CA.
Kristi WatterbergDivision of Neonatology, Department of Pediatrics, University of New Mexico Health Sciences, Albuquerque, NM.
Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network

Funding

Neonatal Research Network Data Coordinating Center (DCC) 2023-2028U24HD095254 · NICHD · RESEARCH TRIANGLE INSTITUTE · PI Abhik Das · 2018 to 2026
$70.2M
Data Ctr for the Cooperative Neonatal Research NetworkU01HD036790 · NICHD · RESEARCH TRIANGLE INSTITUTE · PI DAS, ABHIK · 1998 to 2007
$21.8M
Prophylaxis of adrenal insufficiency to prevent CLDR01HD038540 · NICHD · UNIVERSITY OF NEW MEXICO · PI WATTERBERG, KRISTI L. · 2001 to 2005
$4.6M
NICHD Neonatal Research Network (NRN): Clinical Centers (UG1 Clinical Trial OptionalUG1HD112093 · NICHD · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Matthew Albert Rysavy · 2023 to 2026
$1.4M
NICHD NIH HHS R01 HD038540NICHD NIH HHS U01 HD036790NICHD NIH HHS U24 HD095254NICHD NIH HHS UG1 HD112093
6 · The paper itself

Abstract

objectiveTo examine whether hydrocortisone (HC) modified the relationship of patent ductus arteriosus (PDA) to outcomes among infants born extremely preterm and enrolled in the National Institute of Child Health and Human Development Neonatal Research Network (NRN) HC trial. STUDY

designThis was a posthoc secondary analysis of infants born <30 weeks' gestation and enrolled in the NRN HC Trial. The primary outcome was moderate to severe bronchopulmonary dysplasia (BPD) or death. Secondary outcomes included moderate to severe BPD, death, necrotizing enterocolitis, late-onset sepsis, days of mechanical ventilation, oxygen supplementation, Z-scores for growth, home oxygen, BPD severity, neurodevelopmental impairment, and moderate to severe cerebral palsy. Analyses for interaction between PDA (defined as treatment to achieve PDA closure) and HC were performed for the primary and secondary outcomes.

resultsOf 800 infants enrolled in the NRN HC trial, PDA was treated in 198 HC treated and 197 placebo-treated infants. HC did not modify the relationship of PDA with BPD or death (P = .93). Regardless of HC treatment, PDA was associated with a significant increase in duration of ventilatory support, oxygen supplementation at 36 weeks postmenstrual age (PMA), BPD severity, decreased weight-for-age Z-score at 36 weeks PMA, moderate to severe BPD, or death at 36 weeks PMA and home oxygen support.

conclusionsHC after the second postnatal week did not alter the relationship between PDA and BPD or death among infants born extremely preterm. PDA was associated with several adverse outcomes regardless of HC treatment.

Indexed as

Anti-Inflammatory AgentsBronchopulmonary DysplasiaDuctus Arteriosus, PatentHydrocortisoneInfant, Extremely PrematureInfant, Premature, DiseasesFemaleHumansInfant, NewbornMaleTreatment OutcomeAnti-Inflammatory AgentsHydrocortisonehydrocortisonepatent ductus arteriosus (PDA)preterm infants

Identifiers

PMID40090543
PMCPMC12085282

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.